Founding Director
Wyss Institute for Biologically Inspired Engineering at Harvard University
Donald E. Ingber, MD, PhD is the Founding Director of the Wyss Institute for Biologically Inspired Engineering at Harvard University, Judah Folkman Professor of Vascular Biology at Harvard Medical School and Boston Children’s Hospital, and Hansjörg Wyss Professor of Biologically Inspired Engineering at the Harvard's John A. Paulson School of Engineering and Applied Sciences. He received his BA, MA, MPhil, MD, and PhD from Yale University. Dr. Ingber is a pioneer in the field of biologically inspired engineering, and at the Wyss Institute, he currently leads scientific and engineering teams that cross a broad range of disciplines to develop and commercialize breakthrough bioinspired technologies to advance healthcare and to improve sustainability.
Dr. Ingber is a member of the National Academies of Medicine, Engineering, and Inventors, American Institute for Medical and Biological Engineering, and the American Academy of Arts and Sciences. He was named one of the Top 20 Translational Researchers world-wide in 2012, 2019, and 2020 and has received numerous other national and international honors. Dr. has made great strides in translating his innovations into commercial products and many are now either in clinical trials or currently being sold. One of his most recent breakthroughs is the development of human Organ Chip microfluidic culture devices lined by living human cells that are being used to replace animal testing for drug development, disease modeling, and personalized medicine. His Organ Chip technology was named one of the Top 10 Emerging Technologies by the World Economic Forum and Design of the Year by the London Design Museum. It was also acquired by the Museum of Modern Art (MoMA) in New York City for its permanent design collection. Ingber also has authored more than 500 publications and 200 patents, and founded 8 companies, including Emulate Inc., the leading manufacturer of Organ Chip systems.
Human Organ Chips for Toxicology, Disease Modeling, and Drug Development (Plenary 2)
Wednesday, November 19, 2025
8:00 AM - 8:55 AM (MT)